www.novartis.com
Open in
urlscan Pro
172.64.154.11
Public Scan
Submitted URL: http://novartis.com/
Effective URL: https://www.novartis.com/
Submission: On May 13 via manual from US — Scanned from DE
Effective URL: https://www.novartis.com/
Submission: On May 13 via manual from US — Scanned from DE
Form analysis
2 forms found in the DOMGET /search
<form action="/search" method="get" id="views-exposed-form-global-search-global-search" accept-charset="UTF-8" class="views-exposed-form-global-search-global-search" data-once="bef-auto-submit">
<div class="wrap-global-search-result container">
<div class="js-form-item js-form-type-search-api-autocomplete form-type-search-api-autocomplete js-form-item-keyword form-item-keyword form-no-label mb-3">
<label for="edit-keyword" class="visually-hidden">Search</label>
<div>
<input placeholder="Search" data-drupal-selector="edit-keyword" data-search-api-autocomplete-search="global_search" class="form-autocomplete form-text form-control arc-input ui-autocomplete-input"
data-autocomplete-path="/search_api_autocomplete/global_search?display=global_search&&filter=keyword" type="text" id="edit-keyword" name="keyword" value="" size="30" maxlength="128" data-once="autocomplete search-api-autocomplete"
autocomplete="off">
</div>
</div>
<div data-drupal-selector="edit-actions" class="form-actions js-form-wrapper form-wrapper mb-3" id="edit-actions">
<div>
<input data-bef-auto-submit-click="" data-drupal-selector="edit-submit-global-search" type="submit" id="edit-submit-global-search" value="Search" class="button js-form-submit form-submit btn btn-primary form-control arc-input">
</div>
</div>
</div>
<div class="search-clear-all" style="display: none;">
<div>
<input onclick="clearAllFilterButton(); return false;" data-drupal-selector="edit-button" type="submit" id="edit-button" name="op" value="Clear All" class="button js-form-submit form-submit form-control arc-input">
</div>
</div>
</form>
GET /search
<form action="/search" method="get" id="search-block-form" accept-charset="UTF-8" class="search-form search-block-form form-row">
<div class="js-form-item js-form-type-textfield form-type-textfield js-form-item-keyword form-item-keyword form-no-label mb-3">
<label class="searchForm visually-hidden" for="edit-keys">Search</label>
<div>
<input placeholder="Search" id="edit-keys" data-drupal-selector="edit-keyword" type="text" name="keyword" value="" size="60" maxlength="128" class="form-text form-control arc-input">
</div>
</div>
<div data-drupal-selector="edit-actions" class="form-actions js-form-wrapper form-wrapper mb-3" id="edit-actions--2">
<div>
<input data-drupal-selector="edit-submit" type="submit" id="edit-submit" value="Search" class="button js-form-submit form-submit btn btn-primary form-control arc-input">
</div>
</div>
</form>
Text Content
Skip to main content * Search Search Global | en Choose Location * International * Americas * Asia Pacific * Europe * Middle East & Africa Global | English Novartis Foundation | English(link is external) Argentina | Español Brazil | Português Canada | English Canada | Français Central America | Español Colombia | Español Mexico | Español United States | English Australia | English Bangladesh | English Hong Kong S.A.R. | 繁體中文 India | English Indonesia | English Japan | 日本語 Korea | 한국어 Mainland China | 中文 Malaysia | English Pakistan | English Philippines | English Singapore | English Taiwan | 繁體中文 Thailand | ภาษาไทย Austria | Deutsch Belgium | Français Belgium | Nederlands Bulgaria | Български Czech Republic | Česky Czech Republic | English Denmark | Dansk Estonia | Eesti Finland | Suomalainen France | Français Germany | Deutsch Greece | Ελληνικά Hungary | Magyar Ireland | English Italy | Italiano Latvia | Latvian Lithuania | Lithuanian Netherlands | Nederlands Norway | Norsk Poland | Polski Portugal | Português Romania | Română Russia | Русский Serbia | Srpski Slovakia | Slovensky Slovenia | Slovenščina Slovenia | English Spain | Español Sweden | Svenska Switzerland | Deutsch Switzerland | Français Türkiye | Türkçe United Kingdom | English Egypt | English Israel | עברית Saudi Arabia | العربية South Africa | English Global Choose Location international International Americas Asia Pacific Europe Middle East & Africa Argentina | Español Australia | English Austria | Deutsch Bangladesh | English Belgium | Français Belgium | Nederlands Brazil | Português Bulgaria | Български Canada | English Canada | Français Central America | Español Colombia | Español Czech Republic | Česky Czech Republic | English Denmark | Dansk Egypt | English Estonia | Eesti Finland | Suomalainen France | Français Germany | Deutsch Greece | Ελληνικά Hong Kong S.A.R. | 繁體中文 Hungary | Magyar India | English Indonesia | English Ireland | English Israel | עברית Italy | Italiano Japan | 日本語 Korea | 한국어 Latvia | Latvian Lithuania | Lithuanian Mainland China | 中文 Malaysia | English Mexico | Español Netherlands | Nederlands Norway | Norsk Global | English Novartis Foundation | English(link is external) Pakistan | English Philippines | English Poland | Polski Portugal | Português Romania | Română Russia | Русский Saudi Arabia | العربية Serbia | Srpski Singapore | English Slovakia | Slovensky Slovenia | Slovenščina Slovenia | English South Africa | English Spain | Español Sweden | Svenska Switzerland | Deutsch Switzerland | Français Taiwan | 繁體中文 Thailand | ภาษาไทย Türkiye | Türkçe United Kingdom | English United States | English * Menu * About * Board of Directors * Joerg Reinhardt * Simon Moroney * Nancy C. Andrews * Ton Buechner * Patrice Bula * Elizabeth (Liz) Doherty * Ana de Pro Gonzalo * Bridgette Heller * Daniel Hochstrasser * Frans van Houten * Charles L. Sawyers * William T. Winters * John D. Young * Charlotte Pamer-Wieser * Executive Committee * Vasant (Vas) Narasimhan * Shreeram Aradhye * Victor Bulto * Aharon (Ronny) Gal * Karen L. Hale * Patrick Horber * Harry Kirsch * Rob Kowalski * Steffen Lang * Fiona Marshall * Klaus Moosmayer * Lutz Hegemann * Kees Roks * Michelle Weese * Products * Therapeutic areas * Cardiovascular, renal and metabolic * Immunology * Neuroscience * Oncology * People and culture * Diversity, equity and inclusion * Equity * Inclusivity * Parental leave * Society * Novartis Gene Therapies * Manufacturing * Quality * Audit program * Novartis quality management system (QMS) * Product and patient safety training * Regulatory inspections * Product recalls * Third-party suppliers * Awards and recognition About Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. * Patients and caregivers * Novartis commitment to patients and caregivers * Diseases * Patient organization funding * Patients perspectives stories Patients and caregivers Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting. * Healthcare professionals * Medical congresses and events * Abstract summaries for EULAR * Abstract summaries for ACR * ASCO annual meeting * Products * Novartis pipeline * Managed access programs * Novartis Gene Therapies managed access program * Novartis external funding * Healthcare professional resources by country * Investigator-initiated trials / studies * Novartis medical information * Submit medical enquiry Healthcare professionals Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information. * Research and development * Technology platforms * Research disease areas * Cardiovascular and metabolic disease research at Novartis * DAx: exploratory disease research at Novartis * Global Health disease area research at Novartis * Immunology disease research at Novartis * Neuroscience research at Novartis * Oncology research at Novartis * Ophthalmology research at Novartis * Novartis pipeline * Research collaborations * Collaborations Research & development Discover how Novartis turns breakthrough science into transformative, high-value treatments. * ESG * Access * Creating sustainable business models * Value-based pricing * Sub-Saharan Africa * Donations * Novartis access principles * Novartis oncology access * Patents and licensing * Environmental sustainability * Climate * Waste * Water * Ethics, risk and compliance * Ethical behavior * Compliance * Human rights * Learning and engagement * Risk management * Global health * Pandemic preparedness * Avoidable blindness * Chagas disease * Leprosy * Malaria * Sickle cell disease (SCD) * Novartis Foundation (link is external) * Diversity, equity and inclusion * ESG index * Reporting and transparency hub * Novartis in Society Integrated Report * ESG rating performance * Targets * Patient organization funding * Payments to healthcare professionals * Public policy * A living wage * A safe workplace * Animal research Environmental, social and governance Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report. * Investors * Event calendar * Financial data * Novartis annual results * Novartis quarterly results * Novartis SEC filings * Product sales * Fixed-income securities * Expected currency impact * Share data and analysis * Share monitor * Dividend information * Share ownership * Share overview * Return on investment calculator * Shareholder information * General Meetings * American Depositary Receipts (ADR) * Share buyback * Frequently asked questions * Company overview * Corporate governance * Reporting and transparency hub * Novartis in Society Integrated Report * Reporting archive * ESG rating performance * Publications order form * ESG Investors Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting. * News * News archive * Media library * Stories * Subscribe News Information for journalists including media releases, statements, stories, multimedia resources and more. * Careers * Career search * Our business functions * Careers in research and development * Careers in operations * Careers in commercial and sales * Careers in global functions * Why Novartis * Career hub * Temporary contracts (link is external) * Early careers * Graduates * Students * US Biomedical Research internship programs * Community exploration and learning lab (CELL) Careers Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today. * Clinical trials * Partnering * Supplier portal * Report side effects * Contacts Home Working together, we can reimagine medicine to improve and extend people’s lives. Header REIMAGINING MEDICINE TOGETHER Working together, we can reimagine medicine to improve and extend people’s lives. DISCOVER OUR MEDICINES Our innovative medicines address society’s greatest disease burdens and restore possibility for patients. EXPLORE OUR SCIENCE Discover how we unravel the mysteries of biology and develop new technologies to fight disease and change lives. LEARN ABOUT OUR IMPACT Creating a medicine is just the beginning of the journey. Discover how we embrace societal impact as a core business objective. NOVARTIS FINANCIAL RESULTS – Q1 2024 Novartis announced the company’s financial results for the first quarter of 2024. Learn more LATEST NEWS May 02, 2024 * Media Update NOVARTIS ENTERS AGREEMENT TO ACQUIRE MARIANA ONCOLOGY, STRENGTHENING RADIOLIGAND THERAPY PIPELINE Apr 24, 2024 * Media Release NOVARTIS AND MEDICINES FOR MALARIA VENTURE ANNOUNCE POSITIVE EFFICACY AND SAFETY DATA FOR A NOVEL TREATMENT FOR BABIES <5 KG WITH MALARIA Apr 23, 2024 * Media Release NOVARTIS RADIOLIGAND THERAPY LUTATHERA® FDA APPROVED AS FIRST MEDICINE SPECIFICALLY FOR PEDIATRIC PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS All news THE BURDEN OF IGAN IgAN nephropathy (IgAN) is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide. Novartis is working to slow the progression of this disease and extend a dialysis-free life in patients. Learn more NOVARTIS IN SOCIETY INTEGRATED REPORT 2023 Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society. View the online summary WELCOME TO WHERE WE THRIVE TOGETHER Working together. Learning together. Thriving together. Discover how you can join us in changing people's lives. Join us RESOURCE LINKS About Novartis Healthcare Professionals Patients and Caregivers Pipeline Products NOVARTIS WORKING TOGETHER Working together * Patients and caregivers * Healthcare professionals * Researchers * Job seekers * Journalists * Investors TOPICS Topics * My Cancer. My Words. * Access * Diversity * ESG * SpeakUp EXPLORE Explore * Pipeline * Products * Clinical trials * Partnering * Stories THERAPEUTIC AREAS Therapeutic areas * Cardiovascular, renal and metabolic * Immunology * Neuroscience * Oncology * (link is external) * (link is external) * (link is external) * (link is external) * (link is external) Search FOOTER BOTTOM Footer Bottom © 2024 Novartis AG * Terms of use * Privacy * Cookie Settings * Contacts * Locations * Site map * Open source * Web accessibility Novartis Site Directory This site is intended for a global audience YOUR PRIVACY IS IMPORTANT FOR US. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies, select “Cookie settings” for managing the different cookies or select “Reject all” for using only strictly necessary cookies. You can change your cookie settings at any point of time by pressing the cookie settings link on the website. Cookie Settings Reject all Accept all COOKIE PREFERENCE CENTER When you visit any website, it may store or retrieve information on your browser by using cookies. The cookies are set to expire when the information is no longer needed or after a maximum period of 13 months. You can choose to allow or not to allow some specific types of cookies. Click on the different category headings below to find out more. Please note that blocking some types of cookies may impact your experience on the site and the services we are able to offer. Accept all MANAGE CONSENT PREFERENCES STRICTLY NECESSARY COOKIES Always Active These cookies are necessary for our websites to function and for measurement. We do not allow opt-out rights with respect to these cookies. Cookies Details PERFORMANCE COOKIES Performance cookies These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. Cookies Details FUNCTIONAL COOKIES Functional cookies These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly. Cookies Details TARGETING COOKIES Targeting cookies If you provided your email for marketing or disease awareness purposes, you may need to provide further information to enable us to fully honor your preferences. Click here to learn more. Cookies Details Back Button COOKIE LIST Search Icon Filter Icon Clear checkbox label label Apply Cancel Consent Leg.Interest checkbox label label checkbox label label checkbox label label Save choices